Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Non Operating Income (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Non Operating Income data on record, last reported at $3.5 million in Q3 2025.

  • For Q3 2025, Non Operating Income fell 2.99% year-over-year to $3.5 million; the TTM value through Sep 2025 reached $6.9 million, up 19.76%, while the annual FY2024 figure was -$247000.0, 102.45% down from the prior year.
  • Non Operating Income reached $3.5 million in Q3 2025 per STOK's latest filing, down from $3.8 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $7.4 million in Q3 2023 and bottomed at -$3.3 million in Q4 2024.
  • Average Non Operating Income over 4 years is $1.9 million, with a median of $2.2 million recorded in 2022.
  • Peak YoY movement for Non Operating Income: plummeted 227.25% in 2024, then skyrocketed 8052.08% in 2025.
  • A 4-year view of Non Operating Income shows it stood at $2.2 million in 2022, then rose by 21.16% to $2.6 million in 2023, then tumbled by 227.25% to -$3.3 million in 2024, then skyrocketed by 203.65% to $3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $3.5 million in Q3 2025, $3.8 million in Q2 2025, and $2.9 million in Q1 2025.